[The screening of immune donors in organized collectives]. / Skrining immunnykh donorov v organizovannykh kollektivakh.

Use of blood of reconvalescents from infectious diseases along with screening of blood from non-immunized donors permits procuring new sources of immune blood preparations with high content of specific antibodies (keeping strictly to the existing normative-instructional documents on donorship). Screening of immune donors in military collective bodies is a worth-while exercise both in medical and organizational respects owing to the contingents being homogeneous in sex, age and physiologic status.

[Human specific transfer factor to Staphylococcus aureus antigens]. / Liuds'kyi spetsyfichnyi Faktor perenosu do antyheniv Staphylococcus aureus.

Immunobiological properties of human specific transfer factor (TF) to Staphylococcus aureus antigens were studied. It is shown that this TF activated human leucocytes in vitro as well as in vivo. Antigen specificity of TF's immunomodulating effects is also shown. In vitro we used leucocyte migration inhibition test (IML), macrophage inhibition test (MPI) and rosette formation (E-ros). For testing in vivo we used delayed type hypersensitivity (DTH) skin tests.

[Evaluation of the effectiveness of a specific immunoglobulin against hepatitis A]. / Otsenka éffektivnosti spetsificheskogo immunoglobulina protiv gepatita A.

The present work deals with the controlled trial aimed at the study of the effectiveness of specific immunoglobulin against hepatitis A, developed in the USSR. This immunoglobulin is prepared from carefully selected blood sera from persons who have had hepatitis A. In accordance with the program approved by the USSR Ministry of Health, two trials were organized among the most susceptible groups of the population: organized groups of preschool children and young adults. During 6 months of the subsequent surveillance carried out in both age groups, the highest morbidity rate in hepatitis A was registered among the nonimmunized subjects. Morbidity rate among the subjects immunized with common commercial immunoglobulin was 3-7 times higher than among those immunized with the specific preparation, but a small size of the groups and a low morbidity level prevented the statistically significant confirmation of this higher effectiveness. Specific immunoglobulin produced a statistically significant (t = 2.72 and 2.4) decrease in morbidity rate among the immunized subjects in both age groups in comparison with morbidity rate among the nonimmunized ones.